Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

VitaNova Life Sciences (YJGJ) Operating Income (2017 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Operating Income for 9 consecutive years, with $99170.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income rose 58.42% year-over-year to $99170.0, compared with a TTM value of $1.3 million through Oct 2025, up 391.7%, and an annual FY2025 reading of $1.2 million, up 487.62% over the prior year.
  • Operating Income was $99170.0 for Q4 2025 at VitaNova Life Sciences, up from -$32440.0 in the prior quarter.
  • Across five years, Operating Income topped out at $1.1 million in Q2 2025 and bottomed at -$45414.0 in Q3 2024.
  • Average Operating Income over 5 years is $85843.8, with a median of $1937.0 recorded in 2022.
  • The sharpest move saw Operating Income plummeted 1236.22% in 2023, then surged 1730.43% in 2025.
  • Year by year, Operating Income stood at -$29991.0 in 2021, then soared by 107.12% to $2134.0 in 2022, then tumbled by 510.26% to -$8755.0 in 2023, then surged by 815.02% to $62600.0 in 2024, then soared by 58.42% to $99170.0 in 2025.
  • Business Quant data shows Operating Income for YJGJ at $99170.0 in Q4 2025, -$32440.0 in Q3 2025, and $1.1 million in Q2 2025.